Structure of a Potential Therapeutic Antibody Bound to Interleukin-16 (IL-16)
Gareth Hall(University of Leicester), Mark D. Carr(University of Leicester), Andrew Merritt(LifeArc), Simon Fox(LifeArc), Catherine Kettleborough(LifeArc), David J. Matthews(Sunesis (United States)), Richard Bayliss(University of Leeds), Frederick W. Muskett(University of Leicester), Eilish Cullen(LifeArc), Joanne Arnold(LifeArc), William W. Cruikshank(Boston University), Richard Cowan(University of Leicester), Debra L. Taylor(LifeArc), Kovilen Sawmynaden(LifeArc)
Cited by 12
Related Papers
Efficiency of signalling through cytokine receptors depends critically on receptor orientation
|Nature|1998|555
Immunoglobulin Activation of T Cell Chemoattractant Expression in Fibroblasts from Patients with Graves’ Disease Is Mediated Through the Insulin-Like Growth Factor I Receptor Pathway
|The Journal of Immunology|2003|294
Interleukin-16
|Journal of Leukocyte Biology|2000|277
Molecular and functional analysis of a lymphocyte chemoattractant factor: association of biologic function with CD4 expression.
|Proceedings of the National Academy of Sciences|1994|270
Interleukin 16 and its function as a CD4 ligand
|Immunology Today|1996|255